Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
男人的余味偷
发表于 2024-6-25 19:08:19
1217
0
0
On June 25th, the National Medical Products Administration (NMPA) approved the marketing application of Novo Nordisk's Novo Nordisk developed and produced Novo Nordisk's Novo Nordisk Injection (for long-term weight management) in China. Regarding whether the drug will participate in this year's national medical insurance negotiations, Novo Nordisk responded by stating that it will immediately initiate various work such as online listing and hospital medication administration in various regions after Novo Nordisk's approval, in order to help obese patients use this innovative drug for treatment as soon as possible.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
猜你喜欢
- Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
- The first domestically produced Smegglutide has submitted a marketing application, but it is still far from being used for weight loss
- Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
- Longest Clinical Study of Smegglutide Published: Continuous Four Years of Medication Can Maintain 10% Weight Loss
- Can Smegglutide Help Quit Alcohol? Novo Nordisk's latest liver disease research will provide answers
- Novo Nordisk responds that semaglutide may cause male impotence
- Smegglutide has been approved for the treatment of obesity in China, with a supply chain gap of over 70 billion US dollars in the market
- How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
-
苹果知名分析师郭明錤周四（10月31日）在社交媒体上发文表示，苹果明年可能会减少对芯片制造商博通Wi-Fi芯片的依赖，并推出自己的处理器。 郭明錤在社交媒体平台X上写道，“在2025年下半年的新产品（例如iPh ...- uturn
- 昨天 14:42
- 支持
- 反对
- 回复
- 收藏
-
10月30日，小鹏汽车生态企业小鹏汇天宣布，旗下分体式飞行汽车“陆地航母”即将亮相2024中国航展，11月12日将在中国航展第二展区（斗门莲洲）进行全球首次公开飞行，同时“陆地航母”也将在珠海国际航展中心8号 ...- yxtianyouyou
- 前天 11:43
- 支持
- 反对
- 回复
- 收藏
-
交易所监管文件显示，当地时间11月1日，亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票，预计套现约30.5亿美元。今年7月，贝索斯已申请额外出售约2500万股亚马逊股票，按当时股价计算可套现约50亿美元。 ...- blueskybb
- 10 小时前
- 支持
- 反对
- 回复
- 收藏
-
近日，凯撒海湾目的地（山东）运营管理有限责任公司（简称“凯撒海湾”）与携程旅悦集团签署战略合作协议，双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...- llyyy2008
- 9 小时前
- 支持
- 反对
- 回复
- 收藏
